DiaMedica Therapeutics, Inc. (DMAC)
8.02
0.00 (0.00%)
USD |
NASDAQ |
Nov 20, 10:20
DiaMedica Therapeutics Cash from Operations (Quarterly) : -8.641M for Sept. 30, 2026
Cash from Operations (Quarterly) Chart
Historical Cash from Operations (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2026 | -8.641M |
| June 30, 2026 | -8.034M |
| March 31, 2026 | -9.082M |
| December 31, 2025 | -7.900M |
| September 30, 2025 | -6.617M |
| June 30, 2025 | -7.858M |
| March 31, 2025 | -7.149M |
| December 31, 2024 | -6.025M |
| September 30, 2024 | -4.488M |
| June 30, 2024 | -4.440M |
| March 31, 2024 | -6.653M |
| December 31, 2023 | -3.580M |
| September 30, 2023 | -4.824M |
| June 30, 2023 | -5.066M |
| March 31, 2023 | -5.089M |
| December 31, 2022 | -2.448M |
| September 30, 2022 | -2.232M |
| June 30, 2022 | -2.470M |
| March 31, 2022 | -3.888M |
| December 31, 2021 | -2.779M |
| September 30, 2021 | -2.904M |
| June 30, 2021 | -2.188M |
| March 31, 2021 | -4.313M |
| December 31, 2020 | -3.202M |
| September 30, 2020 | -2.486M |
| Date | Value |
|---|---|
| June 30, 2020 | -0.7883M |
| March 31, 2020 | -2.978M |
| December 31, 2019 | -1.858M |
| September 30, 2019 | -1.306M |
| June 30, 2019 | -2.852M |
| March 31, 2019 | -3.134M |
| December 31, 2018 | |
| September 30, 2018 | -1.799M |
| June 30, 2018 | -1.003M |
| March 31, 2018 | -0.935M |
| December 31, 2017 | -0.9881M |
| September 30, 2017 | -0.8278M |
| June 30, 2017 | -1.405M |
| March 31, 2017 | -0.8232M |
| December 31, 2016 | |
| September 30, 2016 | -0.9353M |
| June 30, 2016 | -0.4272M |
| March 31, 2016 | -0.3959M |
| December 31, 2015 | -0.3726M |
| September 30, 2015 | -0.1165M |
| June 30, 2015 | -0.5838M |
| March 31, 2015 | -0.3465M |
| December 31, 2014 | -0.1147M |
| September 30, 2014 | -0.7268M |
| June 30, 2014 | -1.855M |
Cash From Operations Definition
Represents the net cash flow from the company's business operations.
Cash from Operations (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Operations (Quarterly) Benchmarks
| Arrowhead Pharmaceuticals, Inc. | -192.40M |
| Nektar Therapeutics | -71.93M |
| Fortress Biotech, Inc. | -6.197M |
| ACADIA Pharmaceuticals, Inc. | 11.50M |
| Alnylam Pharmaceuticals, Inc. | 340.98M |
Cash from Operations (Quarterly) Related Metrics
| Cash from Investing (Quarterly) | 10.25M |
| Cash from Financing (Quarterly) | 0.1097M |
| Free Cash Flow | -33.68M |
| Free Cash Flow Per Share (Quarterly) | -0.1604 |
| Free Cash Flow to Equity (Quarterly) | -8.623M |
| Free Cash Flow to Firm (Quarterly) | -8.651M |
| Free Cash Flow Yield | -7.78% |